Please assess the completion status of the following clinical trial:

Trial Title: Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed a current IRB/IEC-approved informed consent form~* Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria~* On a stable regimen of antiparkinson's medications , including any levodopa preparation administered not less than three times daily, and willing to continue the same doses and regimens during study participation~* Experiencing troublesome dyskinesia following levodopa dosing (peak dose dyskinesia)~* Able to understand and complete a standardized PD home diary, following training~Exclusion Criteria:~* History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain stimulation)~* History of seizures or stroke/TIA within 2 years of screening~* History of cancer within 5 years of screening, except adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer~* Estimated GFR \< 50 mL/min/1.73m2~* Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening~* If female, is pregnant or lactating, or has a positive pregnancy test result pre-dose~* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment~* Treatment with an investigational drug or device within 30 days prior to screening~* Treatment with an investigational biologic within 6 months prior to screening

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): None
- Treatment B (Type: ACTIVE_COMPARATOR): Low dose ADS-5102 (amantadine extended release)
- Treatment C (Type: ACTIVE_COMPARATOR): A mid-dose ADS-5102 (amantadine extended release)
- Treatment D (Type: ACTIVE_COMPARATOR): High dose ADS-5102 (amantadine extended release)

Based on this trial design, predict the completion outcome and termination type (if applicable).